Skip to main content

memo - Magazine of European Medical Oncology OnlineFirst articles

03.07.2020 | review Open Access

Patient-reported outcomes and psycho-oncological screening in hematology: a practical example of routine electronic monitoring

Patient-reported outcomes (PROs) have gained increasing importance in oncology. PROs can supplement medical treatment with important information about the patient’s quality of life (QoL), which is typically assessed using standardized …

MSc Jens Lehmann, Lisa M. Wintner, Monika Sztankay, Wolfgang Willenbacher, Roman Weger, Walpurga Weyrer, Gerhard Rumpold, Bernhard Holzner

30.06.2020 | case report

Four lines of immunochemotherapy combinations in a young patient with an aggressive metastatic colorectal cancer

We report on a 42-year-old woman with colorectal cancer of the sigmoid colon with synchronous pulmonary metastases being treated since June of 2016. With a poorly differentiated, KRAS, NRAS and BRAF wildtype cancer and an advanced stage of the …

Frédéric H. Witte, Wolfgang Hilbe, Ercan Müldür

23.06.2020 | short review Open Access

Future perspectives of fertility preservation in women

Fertility preservation in women has become well established over the last two decades. Nevertheless, options for cancer survivors need to be improved to regain ovarian functioning, ideally leading to pregnancy and live birth. Techniques to protect …

MD, MA Bettina Böttcher, MD Katharina Winkler-Crepaz

09.06.2020 | short review Open Access

Homologous recombination deficiency in breast cancer

BRCA mutation-related DNA repair deficiencies increase the individual sensitivity to DNA-targeting agents. Therefore, the patient’s BRCA mutational status is evaluated in clinical practice as a predictive marker in response to platinum salts and …

MD BA Dr. Thomas Bartl, MD PhD Alex Farr

09.06.2020 | review Open Access

Geriatric oncology: questions, answers and guidelines

Raising awareness of the necessity to adapt cancer therapy to the individual needs and resources of elderly cancer patients is the mission for geriatric oncology in the 21st century. Since its beginnings around the turn of the millennium [ 1 ] …

MD, PhD Matthias Unseld, MD Christine Marosi

04.06.2020 | short review

Particle therapy in head and neck cancer—expanding therapeutic options

The management of head and neck tumors is challenging and requires a multidisciplinary approach. Besides the common histology of squamous cell cancer, other histologies like adenoid cystic carcinoma, mucosal melanoma, and adenocarcinoma are often …

MD, PhD Petra Georg

26.05.2020 | short review

Myeloid diseases—Chronic Myeloid Leukemia (CML)—report from ASH 2019 on new developments

The recent American Society of Hematology (ASH) annual meeting, held in Orlando, Florida, in December 2019 was an exciting meeting for researchers and clinicians working in the field of chronic myeloid leukemia (CML), as well as for patients …

Prim. Univ.-Prof. Dr. Andreas L. Petzer

26.05.2020 | original report

Rectal cancer among younger Egyptian patients—clinico-pathological features and oncologic outcomes: A single institution experience

Our younger rectal carcinoma cases had poorer pathologic criteria but the therapy was the crucial factor affecting their survival. Full course of radiotherapy was crucial for better OS of the younger group (P = 0.014), while chemotherapy was …

Amir M. Zaid, MD Engy M. Aboelnaga, Amal Halim, Mohamed Abdelkhalek, Saleh S. Elbalka, Mohamed Zuhdy, Ahmed M. Fareed, Eman M. Ibrahim, Hosam Halim, Islam H. Metwally

25.05.2020 | original report

Biologically effective dose and overall survival in stereotactic body radiotherapy for lung tumors

Stereotactic body radiotherapy (SBRT) delivers precise concentric radiation to a tumor. It is well established that local control depends on the biologically effective dose (BED) delivered, with BED10 of ≥100 as a significant predictor of local …

M.D Osamu Tanaka, M.D. Norihiko Funaguchi, M.D. Sayaka Toyoshi, M.P. Takuya Taniguchi, M.P. Kousei Ono, M.D. Chiyoko Makita, M.D. Masayuki Matsuo

25.05.2020 | original report

Comparison of outcomes of two non-BCNU-containing conditioning regimens used in autologous stem cell transplantation for relapsed/refractory lymphoma

Lymphoma patients, whether Hodgkin (HL) or non-Hodgkin lymphoma (NHL), usually enter into complete remission (CR) with front-line therapy [ 1 ]. However, patients that fail to achieve CR after treatment or that relapse after CR have an inferior …

Amro Mohamed Sedky El-Ghammaz, Maha El-Zimaity, Afaf Abdel-Aziz Abdel-Ghaffar

20.05.2020 | short review Open Access

ASH highlights 2019: “aggressive B-cell lymphoma”

Despite its significant cure rate, diffuse large B‑cell lymphoma (DLBCL) remains a tumor entity of unmet medical need. The 2019 meeting of the American Society of Hematology (ASH) in Orlando, Florida, presented numerous directions, whereby …

Univ.-Prof. Dr. med. Clemens A. Schmitt

20.05.2020 | short review Open Access

New systemic treatment options in mycosis fungoides and Sézary syndrome

Cutaneous T cell lymphomas (CTCL) are a heterogeneous group of rare non-Hodgkin lymphomas. The most common type of CTCL is Mycosis fungoides (MF). Much less common but clinically and histopathologically related to MF is Sézary syndrome (SS). CTCL …

MD Magdalena Seidl-Philipp, MD Van Anh Nguyen

20.05.2020 | short review Open Access

Fertility preservation procedures in girls, adolescents and women

Fertility preservation has become an integral part of standard treatment for young patients with planned gonadotoxic therapy. The decision-making process is an interdisciplinary challenge to both oncologists and radiotherapists involved in the …

MA Dr. Bettina Böttcher, Dr. Maren Goeckenjan

19.05.2020 | short review Open Access

Fine-tuning front-line therapy in chronic lymphocytic leukemia

News from ASH 2019

A deeper understanding of disease biology and the advent of targeted drugs have implemented chemotherapy-free treatment options in chronic lymphocytic leukemia (CLL). With consistently superior outcome data and good tolerability, the Bruton’s …

MD, PhD Jan-Paul Bohn, MD Prof. Dominik Wolf

14.05.2020 | short review Open Access

Nutritional management during treatment for head and neck cancer

Cancer patients are at risk of malnutrition due to disease progress and antitumor therapy. The risk for patients with head and neck cancer is even higher due to the location of their tumor. The development of difficulties in chewing and dysphagia …

MSc Christina Wagner

13.05.2020 | short review

Highlights of ASH 2019—multiple myeloma

The 2019 meeting of the American Society of Hematology (ASH) was dominated by new data from clinical research; effective combinations of mostly recently approved drugs and studies with new promising agents and treatment concepts, currently in the …

Prof. Dr. Heinz Ludwig

13.05.2020 | short review Open Access

Systemic therapy for metastatic salivary gland tumors—challenges and novel concepts

Salivary gland cancers (SGC) are a rare and heterogeneous group of malignancies. Most frequently tumors arise in the parotid gland. The most common histologic subtypes are adenoid cystic carcinoma (ACC) and mucoepidermoid carcinoma (MEC). Rare …

PhD Christoph Minichsdorfer

07.05.2020 | short review Open Access

Treatment options in early triple-negative breast cancer

Update from the San Antonio Breast Cancer Symposium 2019

With a main focus on the early stage triple-negative breast cancer (TNBC), new data on immunotherapy in combination with chemotherapy, the role of capecitabine, the potential of circulating tumor DNA as a predictive tool in the postneoadjuvant …

Christoph Suppan, Marija Balic

21.04.2020 | short review Open Access

Homologous recombination deficiency in epithelial ovarian cancer

Since the introduction of poly-ADP-ribose polymerase (PARP) inhibitor therapy for epithelial ovarian cancer (EOC) patients, testing for aberrations of homologous recombination (HR) repair as a predictive biomarker of therapy response has become an …

Thomas Bartl, Valentina Paspalj, Christoph Grimm

16.04.2020 | short review

Circulating tumour DNA-guided adjuvant chemotherapy in colorectal carcinoma

Approximately 20% of locoregional colorectal carcinoma (CRC) relapse after standard of care treatment. Therefore, it is necessary to personalize our adjuvant strategies and define this subgroup, which remains at high risk after treatment.

MD Andreas Reichinger, Holger Rumpold